Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 83.56
(1.27%)
INR 83.56
(1.27%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.15 Billion INR | -149.21% |
| 2022 | 8.43 Billion INR | -9.41% |
| 2021 | 9.31 Billion INR | -6.26% |
| 2020 | 9.93 Billion INR | -2.64% |
| 2019 | 10.2 Billion INR | -10.65% |
| 2018 | 11.42 Billion INR | 38.92% |
| 2017 | 8.22 Billion INR | -33.66% |
| 2016 | 12.39 Billion INR | -7.36% |
| 2015 | 13.38 Billion INR | -3.95% |
| 2014 | 13.93 Billion INR | 4.36% |
| 2013 | 13.34 Billion INR | 9.24% |
| 2012 | 12.21 Billion INR | 26.4% |
| 2011 | 9.66 Billion INR | 77.27% |
| 2010 | 5.45 Billion INR | 2.07% |
| 2009 | 5.34 Billion INR | 49.89% |
| 2008 | 3.56 Billion INR | 18.47% |
| 2007 | 3 Billion INR | 7.57% |
| 2006 | 2.79 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q1 | 181.99 Million INR | -97.84% |
| 2023 Q3 | 132.04 Million INR | -98.33% |
| 2023 Q4 | -4.15 Billion INR | -3245.21% |
| 2023 Q2 | 7.88 Billion INR | 4232.13% |
| 2023 FY | -4.15 Billion INR | -149.21% |
| 2022 Q3 | 138.68 Million INR | -98.46% |
| 2022 FY | 8.43 Billion INR | -9.41% |
| 2022 Q4 | 8.43 Billion INR | 5985.16% |
| 2022 Q2 | 9.02 Billion INR | 4101.44% |
| 2022 Q1 | 214.77 Million INR | -97.69% |
| 2021 FY | 9.31 Billion INR | -6.26% |
| 2021 Q3 | 173.17 Million INR | -98.19% |
| 2021 Q2 | 9.55 Billion INR | 8135.95% |
| 2021 Q1 | 116 Million INR | -98.83% |
| 2021 Q4 | 9.31 Billion INR | 5279.3% |
| 2020 Q4 | 9.93 Billion INR | 8280.59% |
| 2020 Q3 | 118.57 Million INR | -98.81% |
| 2020 FY | 9.93 Billion INR | -2.64% |
| 2020 Q1 | 105.82 Million INR | -98.96% |
| 2020 Q2 | 9.93 Billion INR | 9284.05% |
| 2019 Q4 | 10.2 Billion INR | 8082.41% |
| 2019 Q2 | 10.62 Billion INR | 0.0% |
| 2019 FY | 10.2 Billion INR | -10.65% |
| 2019 Q3 | 124.74 Million INR | -98.83% |
| 2018 FY | 11.42 Billion INR | 38.92% |
| 2018 Q4 | 11.42 Billion INR | 0.0% |
| 2017 FY | 8.22 Billion INR | -33.66% |
| 2016 FY | 12.39 Billion INR | -7.36% |
| 2015 FY | 13.38 Billion INR | -3.95% |
| 2014 FY | 13.93 Billion INR | 4.36% |
| 2013 FY | 13.34 Billion INR | 9.24% |
| 2012 Q4 | 12.21 Billion INR | 0.0% |
| 2012 FY | 12.21 Billion INR | 26.4% |
| 2012 Q2 | 13.76 Billion INR | 0.0% |
| 2011 FY | 9.66 Billion INR | 77.27% |
| 2010 FY | 5.45 Billion INR | 2.07% |
| 2009 FY | 5.34 Billion INR | 49.89% |
| 2008 FY | 3.56 Billion INR | 18.47% |
| 2007 FY | 3 Billion INR | 7.57% |
| 2006 FY | 2.79 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 94.269% |
| NATCO Pharma Limited | -5.81 Billion INR | 28.605% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 2964.65% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 9087.157% |
| Achyut Healthcare Limited | -3.74 Million INR | -110766.391% |
| Ajanta Pharma Limited | -954.9 Million INR | -334.92% |
| Alkem Laboratories Limited | -1.6 Billion INR | -158.05% |
| Alpa Laboratories Limited | 35.36 Million INR | 11844.069% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 207.428% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 17.145% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 212.448% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 225.89% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -258.717% |
| Brooks Laboratories Limited | 49.48 Million INR | 8492.553% |
| Divi's Laboratories Limited | -39.77 Billion INR | 89.557% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 132.162% |
| Eris Lifesciences Limited | 13.8 Billion INR | 130.081% |
| FDC Limited | -57.75 Million INR | -7091.188% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 3.085% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -46.097% |
| Granules India Limited | 9.28 Billion INR | 144.72% |
| Gufic Biosciences Limited | 3.19 Billion INR | 230.014% |
| Hester Biosciences Limited | 2.29 Billion INR | 281.298% |
| Indoco Remedies Limited | 6.47 Billion INR | 164.127% |
| Ipca Laboratories Limited | 11.41 Billion INR | 136.382% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -198.796% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 314.859% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2118.015% |
| Laurus Labs Limited | 24.38 Billion INR | 117.031% |
| Lupin Limited | 17.19 Billion INR | 124.156% |
| Mankind Pharma Limited | -9.9 Billion INR | 58.084% |
| Medicamen Biotech Limited | 160.31 Million INR | 2690.543% |
| Medico Remedies Limited | 78.67 Million INR | 5378.614% |
| Megasoft Limited | 1.28 Billion INR | 423.056% |
| Piramal Pharma Limited | 42.27 Billion INR | 109.824% |
| RPG Life Sciences Limited | -364.7 Million INR | -1038.759% |
| Sigachi Industries Limited | 859.94 Million INR | 582.942% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -340.97% |
| Unichem Laboratories Limited | 931.91 Million INR | 545.647% |
| Wanbury Limited | 1.1 Billion INR | 475.545% |
| Windlas Biotech Limited | -273.04 Million INR | -1421.043% |
| ZIM Laboratories Limited | 983.6 Million INR | 522.228% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 206.162% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -76.876% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -1569.288% |
| Bal Pharma Limited | 1.26 Billion INR | 428.679% |
| Strides Pharma Science Limited | 23.25 Billion INR | 117.857% |
| Venus Remedies Limited | -267.7 Million INR | -1451.384% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 259.005% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 167.449% |
| Shilpa Medicare Limited | 9.06 Billion INR | 145.791% |
| Aarti Drugs Limited | 5.54 Billion INR | 174.851% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -277.105% |
| Suven Life Sciences Limited | -1.63 Billion INR | -154.368% |
| Ind-Swift Limited | 9.5 Billion INR | 143.677% |
| Valiant Laboratories Limited | -295.03 Million INR | -1307.663% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 247.209% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 141.41% |
| Themis Medicare Limited | 764.96 Million INR | 642.91% |
| Hikal Limited | 7.96 Billion INR | 152.128% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 113.048% |
| Sequent Scientific Limited | 4.17 Billion INR | 199.388% |
| Novartis India Limited | -5.89 Billion INR | 29.503% |
| Wockhardt Limited | 18.27 Billion INR | 122.732% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 115.341% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -22414.664% |
| Neuland Laboratories Limited | -214.05 Million INR | -1840.154% |
| Morepen Laboratories Limited | -231.17 Million INR | -1696.506% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 3559.755% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 525.6% |